| http://www.w3.org/ns/prov#value | - Besides antiplatelet therapies, anticoagulants such as enoxaparin afforded benefits on major ischemic events in patients undergoing primary percutaneous coronary interventions, with superiority comparing outcomes in patients receiving unfractionated heparin [Silvain, J. et al., Abst 15664].
|
